Nigel J. Waters

6.5k citations

58 papers · 3.2k indexed · 2 hit papers · h-index 26

Impact in

Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism
Computational Theory and Mathematics top 1%
- Computational Drug Discovery Methods

Papers in

Pharmacology 13
- Pharmacogenetics and Drug Metabolism 11
Hematology 11
- Acute Myeloid Leukemia Research 11

Co-authors: Franco Lombardo R. Scott Obach Jeremy K. Nicholson R. Duncan Farrant Elaine Holmes Catherine J. Waterfield Rachel L. Jones Robert A. Copeland
Journals: Drug Metabolism and Disposition (6 papers)Molecular Cancer Therapeutics (5 papers)Blood (5 papers)Journal of Medicinal Chemistry (4 papers)Annals of Oncology (3 papers)
Partner nations: United States United Kingdom Switzerland

In The Last Decade

Nigel J. Waters

52 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia 2013 · 546 citations

Peers

Countries citing papers authored by Nigel J. Waters

Since Specialization

Citations

This map shows the geographic impact of Nigel J. Waters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel J. Waters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel J. Waters more than expected).

Fields of papers citing papers by Nigel J. Waters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel J. Waters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel J. Waters. The network helps show where Nigel J. Waters may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Nigel J. Waters, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nigel J. Waters Line = papers co-authored together Nigel J. Waters links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	27MO BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models Annals of Oncology ·Matthew C. Lucas, Melinda S. Merchant, Matthew O’Connor, Sherri Smith, Anthony F. Trombino, Enk B, Rafael Pereira Dubiela, Sudharshan Eathiraj, Nigel J. Waters, Elizabeth Buck	2022	5
2	Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged Leukemia Molecular Cancer Therapeutics ·Carly Campbell, J.P.Jr. Yap, David A. Drubin, Timothy M. Thomson, 倪志安, T P Kennedy, Nigel J. Waters, Edward J. Olhava, Roy M. Pollock, J. Joshua Smith, Robert A. Copeland, Stephen J. Blakemore, Kathrin M. Bernt, Scott R. Daigle	2017	46
3	Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients Annals of Oncology ·Dale L. Bixby, Carlos E. Vigil, Joseph G. Jurcic, Rachel J. Cook, Mikkael A. Sekeres, David A. Rizzieri, Jörge E. Cortes, Robert L. Redner, David P. Steensma, Gail J. Roboz, Tamara K. Moyo, Michael R. McKeown, Nigel J. Waters, Edgar Paúl Suntasig Masabanda, Emmanuelle di Tomaso, Doris Roth, Eytan M. Stein	2017	1
4	A phase 1 study of SY-1365, a selective CDK7 inhibitor, in adult patients with advanced solid tumors Annals of Oncology ·Anthony W. Tolcher, T. Khanh, Emmanuelle di Tomaso, Nigel J. Waters, Edgar Paúl Suntasig Masabanda, David A. Roth, Geoffrey I. Shapiro	2017	2
5	Implications for Metabolite Quantification by Mass Spectrometry in the Absence of Authentic Standards Drug Metabolism and Disposition ·Panos Hatsis, Nigel J. Waters, Upendra A. Argikar	2017	22
6	Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development Drug Metabolism and Disposition ·Nathalie Rioux, Nigel J. Waters	2016	24
7	Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human Cancer Chemotherapy and Pharmacology ·Nigel J. Waters, Sherri Smith, Edward J. Olhava, Kenneth W. Duncan, Richard D. E. Burton, Yuvraj Dhobale, M. Firouzbakht, Roy M. Pollock, Mikel P. Moyer, Richard Chesworth	2015	23
8	Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652 Drug Metabolism and Disposition ·Nathalie Rioux, Lorna H. Mitchell, Philip R. Tiller, J.N. White, C. Wrr-CHER, J. Siboulet, Scott Ribich, Mikel P. Moyer, Robert A. Copeland, Richard Chesworth, Nigel J. Waters	2015	5
9	Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension Bioorganic & Medicinal Chemistry Letters ·Duncan Shaw, M Whitlock, Nicolas Soldermann, Elizabeth R. Sprague, W. Schüler, Eric Vangrevelinghe, Nicholas Duggan, Matthew J. Thomas, Takatoshi Kosaka, Nigel J. Waters, Maurice J. van Eis	2014	35
10	Consideration of the Unbound Drug Concentration in Enzyme Kinetics Methods in molecular biology ·Nigel J. Waters, R. Scott Obach, Li Di	2014	4
11	Potent inhibition of DOT1L as treatment of MLL-fusion leukemia Blood ·Scott R. Daigle, Edward J. Olhava, 正樹北薗, Aravind Basavapathruni, Lei Jin, P. Ann Boriack‐Sjodin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock Hit paper breakdown →	2013	546
12	Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance The Journal of Clinical Pharmacology ·Franco Lombardo, Nigel J. Waters, Upendra A. Argikar, Michelle K. Dennehy, Jenny Zhan, Mithat Gunduz, Shawn Harriman, Giuliano Berellini, Velda R Holthus, R. Scott Obach	2012	72
13	Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State The Journal of Clinical Pharmacology ·Franco Lombardo, Nigel J. Waters, Upendra A. Argikar, Michelle K. Dennehy, Jenny Zhan, Mithat Gunduz, Shawn Harriman, Giuliano Berellini, Velda R Holthus, R. Scott Obach	2012	57
14	Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas Cancer Research ·Tara L. Naylor, Huaping Tang, Boris A. Ratsch, Andreas Enns, Alice Loo, Liqing Chen, Peter Lenz, Nigel J. Waters, W. Schüler, Bernd Dörken, Yung‐Mae Yao, Markus Warmuth, Georg Lenz, Frank Stegmeier	2011	88
15	The Role of Metabonomics at the Interface Between Drug Metabolism and Safety Assessment Current Drug Metabolism ·Nigel J. Waters	2010	6
16	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds Drug Metabolism and Disposition ·R. Scott Obach, Franco Lombardo, Nigel J. Waters Hit paper breakdown →	2008	374
17	Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein Binding Journal of Pharmaceutical Sciences ·Nigel J. Waters, Rachel L. Jones, Gareth Williams, Bindi Sohal	2008	240
18	Advancements in Predictive In Silico Models for ADME Current Chemical Biology ·Kamaldeep K. Chohan, Stuart W. Paine, Nigel J. Waters	2008	15
19	Integrated in Vitro Analysis for the in Vivo Prediction of Cytochrome P450-Mediated Drug-Drug Interactions Drug Metabolism and Disposition ·Dermot F. McGinnity, Nigel J. Waters, Cui Gao-feng, Robert J. Riley	2008	29
20	Quantitative Structure Activity Relationships in Drug Metabolism Current Topics in Medicinal Chemistry ·Kamaldeep K. Chohan, Stuart W. Paine, Nigel J. Waters	2006	26

About Nigel J. Waters

Nigel J. Waters is a scholar working on Pharmacology, Hematology, Oncology, Computational Theory and Mathematics and Spectroscopy, having authored 58 papers that have together received 3.2k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (14 papers), Cancer-related gene regulation (13 papers), Pharmacogenetics and Drug Metabolism (11 papers), Acute Myeloid Leukemia Research (11 papers), Computational Drug Discovery Methods (10 papers), Analytical Chemistry and Chromatography (9 papers), Metabolomics and Mass Spectrometry Studies (7 papers) and Drug Transport and Resistance Mechanisms (7 papers). The work is most often cited by research in Pharmacology (555 citations), Computational Theory and Mathematics (476 citations), Molecular Biology (2.0k citations), Hematology (302 citations) and Spectroscopy (329 citations). Nigel J. Waters has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Franco Lombardo, R. Scott Obach, Jeremy K. Nicholson, R. Duncan Farrant, Elaine Holmes, Catherine J. Waterfield, Rachel L. Jones, Robert A. Copeland, Gareth Williams and Bindi Sohal. Their work appears in journals such as Drug Metabolism and Disposition, Molecular Cancer Therapeutics, Blood, Journal of Medicinal Chemistry and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact